Table 2. Key clinical data.
| Parameter | Expected Values (Ranges) | Distribution (Parameters) | Description and Reference |
|---|---|---|---|
| Weibull survival model of PFS for PC | Scale = 0.1029; Shape = 1.3077; r2 = 0.981 | NA | [24] |
| HR of PFS for PC followed by pemetrexed maintenance | 0.59 | Normal (0.59, 0.161) | Network meta-analysis |
| HR of PFS for gefitinib | 0.48(0.29-0.8) | Normal (0.48, 0.13) | Network meta-analysis |
| HR of PFS for icotinib | 0.4(0.19-0.81) | Normal (0.4, 0.158) | Network meta-analysis |
| Probability of survival after progression | 0.086(0.08-0.093) | Beta (751.1, 7982.7) | [33] |
| EGFR mutation prevalence | 0.47(0.2-0.76) | Normal (0.47, 0.143) | [34] |
| Probability of SAEs from the control strategy | 0.456(0.342-0.57) | Beta (33.6, 40.1) | [24, 35] |
| Probability of SAEs from the pemetrexed strategy | 0.637(0.478-0.796) | Beta (22.4, 12.8) | [24] |
| Probability of SAEs from the gefitinib strategy | 0.1(0.075-0.125) | Beta (53.3, 479.3) | [36] |
| Probability of SAEs from the icotinib strategy | 0.07(0.053-0.088) | Beta (56.3, 747.4) | [36] |
| Body surface area (m2) | 1.72(1.5-1.9) | Normal (1.72, 0.102) | [37] |
PC: pemetrexed plus cisplatin; EGFR: epidermal growth factor receptor; SAEs: serious adverse events (≥ grade 3); PFS: progression-free survival; HR: hazard ratio; NA: not applicable.